PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced that three abstracts, which relate to the safety and efficacy of Microcyn® Technology in the treatment of diabetic foot ulcers, were peer reviewed and presented at DFCon 08 this past week in Hollywood, California. The conference, which is one of the premier diabetic foot conferences in the world, is a showcase for the latest advances in the treatment and care of the diabetic foot. The three abstracts evaluating the use of the Microcyn® Technology were:
